

dictors of poor treatment response in patients with schizophrenia treated with atypical antipsychotics. *BMC Psychiatry* 2018; 18: 376.

8. Stahl SM. Stahl's Essential Psychopharmacology Cambridge University Press 2013: 608.

9. Citrome L, McEvoy JP, Todtenkopf MS, McDonnell D, Weiden PJ. A commentary on the efficacy of olanzapine for the treatment of schizophrenia: the past, present, and future. *Neuropsychiatr Dis Treat* 2019; 15: 2559–2569.

10. Cabaleiro T, Lopez-Rodríguez R, Ochoa D, Roman M, Navalbos J, Abad-Santos F. Polymorphisms influencing olanzapine metabolism and adverse effects in healthy subjects. *Human Psychopharmacology-Clinical and Experimental* 2013; 28: 205–214.

11. Chagraoui A, Thibaut F, Skiba M, Thuillez C, Bourin M. 5-HT_{2C} receptors in psychiatric disorders: A review. *Progress in Neuro-Psychopharmacology & Biological Psychiatry* 2016; 66: 120–135.

12. Perry PJ, Sanger T, Beasley C. Olanzapine plasma concentrations and clinical response in acutely ill schizophrenic patients. *J Clin Psychopharmacol* 1997; 17: 472–477.

13. Hiemke C, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, Eckermann G, et al. Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017. *Pharmacopsychiatry* 2018, 51: e1.

14. Carrillo JA, Herraiz AG, Ramos SI, Gervasini G, Vizcaino S, Benitez J. Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine. *Journal of Clinical Psychopharmacology* 2003; 23: 119–127.

15. Bozikas VP, Papakosta M, Niopas L, Karavatos A, Mirtsou-Fidani V. Smoking impact on CYP1A2 activity in a group of patients with schizophrenia. *European Neuropsychopharmacology* 2004; 14: 39–44.

16. Nozawa M, Ohnuma T, Matsubara Y, Sakai Y, Hatano T, Hanzawa R, Shibata N, et al. The relationship between the response of clinical symptoms and plasma olanzapine concentration, based on pharmacogenetics. *Therapeutic Drug Monitoring* 2008; 30: 35–40.

17. Bondolfi G, Morel F, Crettol SV, Rachid F, Baumann P, Eap CB. Increased clozapine plasma concentrations and side effects induced by smoking cessation in 2 CYP1A2 genotyped patients. *Therapeutic Drug Monitoring* 2005; 27: 539–543.

18. Gaedigk A, Leeder S, Miller N, Hoffman M, Lee M, Phillips M, Pratt V, et al. Pharmacogene Variation Consortium (PharmVar). ed. *Children's Mercy in Kansas City, USA: Pharmacogene Variation Consortium (PharmVar)* 2019.

19. Tay JK, Tan CH, Chong SA, Tan EC. Functional polymorphisms of the cytochrome P450 1A2 (CYP1A2) gene and prolonged QTc interval in schizophrenia. *Prog Neuropsychopharmacol Biol Psychiatry* 2007; 31: 1297–1302.

20. Yasar U, Babaoglu MO, Balibey H, Cetin M, Lundgren S, Rane A, Bozkurt A. Association of the cytochrome P450 1A2*1 F polymorphism with clozapine response in schizophrenic patients. *Pharmazie* 2007; 62: A196–A196.

21. Czerwensky F, Leucht S, Steimer W. CYP1A2*1D and *1 F polymorphisms have a significant impact on olanzapine serum concentrations. *Ther Drug Monit* 2015; 37: 152–160.

22. Ghotbi R, Mannheimer B, Aklilu E, Suda A, Bertilsson L, Eliasson E, Osby U. Carriers of the UGT1A4 142 T>G gene variant are predisposed to reduced olanzapine exposure—an impact similar to male gender or smoking in schizophrenic patients. *Eur J Clin Pharmacol* 2010; 66: 465–474.

23. Mao M, Skogh E, Scordo MG, Dahl ML. Interindividual variation in olanzapine concentration influenced by UGT1A4 L48V polymorphism in serum and upstream FMO polymorphisms in cerebrospinal fluid. *J Clin Psychopharmacol* 2012; 32: 287–289.

24. Bozina N, Kuzman MR, Medved V, Jovanovic N, Sertic J, Hotujac L. Associations between MDR1 gene polymorphisms and schizophrenia and therapeutic response to olanzapine in female schizophrenic patients. *Journal of Psychiatric Research* 2008; 42: 89–97.

25. Rao VV, Dahlheimer JL, Bardgett ME, Snyder AZ, Finch RA,

Sartorelli AC, Piwnica-Worms D. Choroid plexus epithelial expression of MDR1 P-glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier. *Proc Natl Acad Sci U S A* 1999; 96: 3900–3905.

26. Boulton DW, DeVane CL, Liston HL, Markowitz JS. In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. *Life Sci* 2002; 71: 163–169.

27. Tiwari AK, Sodani K, Dai CL, Ashby CR, Chen ZS, Chen ZS. Revisiting the ABCs of Multidrug Resistance in Cancer Chemotherapy. *Current Pharmaceutical Biotechnology* 2011; 12: 570–594.

28. Fardel O, Lecœur V, Guilloze A. The P-glycoprotein multidrug transporter. *General Pharmacology* 1996; 27: 1283–1291.

29. Schinkel AH, Wagenaar E, Mol CAAM, van Deemter L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. *Journal of Clinical Investigation* 1996; 97: 2517–2524.

30. Lankas GR, Wise LD, Cartwright ME, Pippert T, Umbenhauer DR. Placental P-glycoprotein deficiency enhances susceptibility to chemically induced birth defects in mice. *Reproductive Toxicology* 1998; 12: 457–463.

31. Lin YC, Ellingrod VL, Bishop JR, Miller DD. The relationship between P-glycoprotein (PGP) polymorphisms and response to olanzapine treatment in schizophrenia. *Therapeutic Drug Monitoring* 2006; 28: 668–672.

32. Kuzman MR, Medved V, Bozina N, Grubisin J, Jovanovic N, Sertic J. Association study of MDR1 and 5-HT_{2C} genetic polymorphisms and antipsychotic-induced metabolic disturbances in female patients with schizophrenia. *Pharmacogenomics Journal* 2011; 11: 35–44.

33. Jovanovic N, Bozina N, Lovric M, Medved V, Jakovljevic M, Peles AM. The role of CYP2D6 and ABCB1 pharmacogenetics in drug-naïve patients with first-episode schizophrenia treated with risperidone. *European Journal of Clinical Pharmacology* 2010; 66: 1109–1117.

34. al Mouaffak F, Oussama K, Picard V, Bonhomme-Faivre L. Ultra-Resistant Schizophrenia Is Not Associated With the Multidrug-Resistant Transporter 1 (MDR1) Gene rs1045642 Variant. *Journal of Clinical Psychopharmacology* 2011; 31: 2.

35. Lee ST, Ryu S, Kim SR, Kim MJ, Kim JW, Lee SY, et al. Association study of 27 annotated genes for clozapine pharmacogenetics: validation of preexisting studies and identification of a new candidate gene, ABCB1, for treatment response. *J Clin Psychopharmacol* 2012; 32: 441–448.

36. Saiz-Rodríguez M, Belmonte C, Román M, Ochoa D, Jiang-Zheng C, Koller D, Mejía G, et al. Effect of ABCB1 C3435T Polymorphism on Pharmacokinetics of Antipsychotics and Antidepressants. *Basic Clin Pharmacol Toxicol* 2018; 123: 474–485.

37. Tovilla-Zarate C, Vargas I, Hernandez S, Fresan A, Aguilar A, Escamilla R, Saracco R, et al. Association study between the MDR1 gene and clinical characteristics in schizophrenia. *Revista Brasileira De Psiquiatria* 2014; 36: 227–232.

38. Pan J, Han J, Wu J, Huang H, Yu Q, Sheng L. MDR1 Single Nucleotide Polymorphism G2677T/A and Haplotype Are Correlated with Response to Docetaxel-Cisplatin Chemotherapy in Patients with Non-Small-Cell Lung Cancer. *Respiration* 2009; 78: 49–55.

39. Fernandes B, Steiner J, Berk M, Molendijk M, Gonzalez-Pinto A, Turck C, Nardin P, et al. Peripheral brain-derived neurotrophic factor in schizophrenia and the role of antipsychotics: meta-analysis and implications. *Molecular Psychiatry* 2015; 20: 1108–1119.

40. Můj případ – Je kyselina acetylsalicylová v každé tabletě stejná? *Bulletin Sdružení praktických lékařů ČR* 2015; 25: 57–58.

41. Huang E, Hettige NC, Zai G, Tomasi J, Huang J, Zai CC, Pivac N, et al. BDNF Val66Met polymorphism and clinical response to antipsychotic treatment in schizophrenia and schizoaffective disorder patients: a meta-analysis. *Pharmacogenomics J* 2019; 19: 269–276.

42. Zai G, Zai C, Chowdhury N, Tiwari A, Souza R, Lieberman J, Meltzer H, et al. The role of brain-derived neurotrophic factor (BDNF) gene variants in antipsychotic response and antipsychotic-induced weight gain. *Progress in Neuro-*

-Psychopharmacology & Biological Psychiatry 2012; 39: 96–101.

43. Abdolmaleky HM, Faraone SV, Glatt SJ, Tsuang MT. Meta-analysis of association between the T102C polymorphism of the 5HT_{2a} receptor gene and schizophrenia. *Schizophrenia Research* 2004; 67: 53–62.

44. Myers RL, Airey DC, Manier DH, Shelton RC, Sanders-Bush E. Polymorphisms in the regulatory region of the human serotonin 5-HT_{2A} receptor gene (HTR2A) influence gene expression. *Biological Psychiatry* 2007; 61: 167–173.

45. Davies MA, Conley Y, Roth BL. Functional SNPs in Genes Encoding the 5-HT_{2A} Receptor Modify the Affinity and Potency of Several Atypical Antipsychotic Drugs. *Biological Research for Nursing* 2011; 13: 55–60.

46. Gu L, Long JX, Yan Y, Chen Q, Pan RD, Xie XF, Mao XX, et al. HTR2A1438A/G polymorphism influences the risk of schizophrenia but not bipolar disorder or major depressive disorder: A meta-analysis. *Journal of Neuroscience Research* 2013; 91: 623–633.

47. Joobor R, Benkelfat C, Brisebois K, Toulouse A, Turecki G, Lal S, Bloom D, et al. T102C polymorphism in the 5HT_{2A} gene and schizophrenia: relation to phenotype and drug response variability. *J Psychiatry Neurosci* 1999; 24: 141–146.

48. Chen RYL, Sham P, Chen EYH, Li T, Cheung EFC, Hui TCK, Kwok CL, et al. No association between T102C polymorphism of serotonin-2A receptor gene and clinical phenotypes of Chinese schizophrenic patients. *Psychiatry Research* 2001; 105: 175–185.

49. Hawi Z, Myakishev MV, Straub RE, O'Neill A, Kendler KS, Walsh D, Gill M. No association or linkage between the 5-HT_{2a}/T102C polymorphism and schizophrenia in Irish families. *American Journal of Medical Genetics* 1997; 74: 370–373.

50. Arranz MJ, Collier DA, Munro J, Sham P, Kirov G, Sodhi M, Roberts G, et al. Analysis of a structural polymorphism in the 5-HT_{2A} receptor and clinical response to clozapine. *Neuroscience Letters* 1996; 217: 177–178.

51. Arranz MJ, Munro J, Birkett J, Bolonna A, Mancama D, Sodhi M, Lesch KP, et al. Pharmacogenetic prediction of clozapine response. *Lancet* 2000; 355: 1615–1616.

52. Saiz PA, Garcia-Portilla MP, Arango C, Morales B, Alvarez V, Coto E, Fernandez JM, et al. Association study of serotonin 2A receptor (5-HT_{2A}) and serotonin transporter (5-HTT) gene polymorphisms with schizophrenia. *Progress in neuro-psychopharmacology & biological psychiatry* 2007; 31: 741–745.

53. Souza RP, de Luca V, Meltzer HY, Lieberman JA, Kennedy JL. Influence of serotonin 3A and 3B receptor genes on clozapine treatment response in schizophrenia. *Pharmacogenetics and Genomics* 2010; 20: 274–276.

54. McMahon F, Buervenich S, Charney D, Lipsky R, Rush A, Wilson A, Sorant A, et al. Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. *American Journal of Human Genetics* 2006; 78: 804–814.

55. Laika B, Leucht S, Heres S, Schneider H, Steimer W. Pharmacogenetics and olanzapine treatment: CYP1A2 (star)1 F and serotonergic polymorphisms influence therapeutic outcome. *Pharmacogenomics Journal* 2010; 10: 20–29.

56. Li J, Hashimoto H, Meltzer HY. Association of Serotonin 2c Receptor Polymorphisms With Antipsychotic Drug Response in Schizophrenia. *Front Psychiatry* 2019; 10: 58.

57. Wallace TJ, Zai CC, Brandl EJ, Müller DJ. Role of 5-HT_{2C} receptor gene variants in antipsychotic-induced weight gain. *Pharmacogenomics Pers Med* 2011; 4: 83–93.

58. Huang XF, Tan YY, Huang X, Wang Q. Effect of chronic treatment with clozapine and haloperidol on 5-HT_{2A} and 2C receptor mRNA expression in the rat brain. *Neuroscience Research* 2007; 59: 314–321.

59. Padin JF, Rodríguez MA, Domínguez E, Dopeso-Reyes IG, Buceta M, Cano E, Sotelo E, et al. Parallel regulation by olanzapine of the patterns of expression of 5-HT_{2A} and D3 receptors in rat central nervous system and blood cells. *Neuropharmacology* 2006; 51: 923–932.

60. Godlewska B, Olajossy-Hilkesberger L, Ciwoniuk M, Olajossy M, Marmurowska-Michalowska K, Limon J, Landowski